Furthermore, medications that target angiogenic pathways, such as VEGF inhibitors (for instance, bevacizumab) [174,175,176], can help normalize the tumor vasculature, thereby increasing the effectiveness of concurrently administered therapies. This evidence concerns the gene VEGFA and neoplasm.